177 related articles for article (PubMed ID: 22931442)
21. Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.
Lange JH; van Stuivenberg HH; Coolen HK; Adolfs TJ; McCreary AC; Keizer HG; Wals HC; Veerman W; Borst AJ; de Looff W; Verveer PC; Kruse CG
J Med Chem; 2005 Mar; 48(6):1823-38. PubMed ID: 15771428
[TBL] [Abstract][Full Text] [Related]
22. Novel antiobesity agents: synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21.
Alvarado M; Decara J; Luque MJ; Hernandez-Folgado L; Gómez-Cañas M; Gómez-Ruiz M; Fernández-Ruiz J; Elguero J; Jagerovic N; Serrano A; Goya P; de Fonseca FR
Bioorg Med Chem; 2013 Apr; 21(7):1708-16. PubMed ID: 23434135
[TBL] [Abstract][Full Text] [Related]
23. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
[TBL] [Abstract][Full Text] [Related]
24. Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice.
Gamble-George JC; Conger JR; Hartley ND; Gupta P; Sumislawski JJ; Patel S
Psychopharmacology (Berl); 2013 Aug; 228(3):401-9. PubMed ID: 23483200
[TBL] [Abstract][Full Text] [Related]
25. ENP11, a potential CB1R antagonist, induces anorexia in rats.
Méndez-Díaz M; Amancio-Belmont O; Hernández-Vázquez E; Ruiz-Contreras AE; Hernández-Luis F; Prospéro-García O
Pharmacol Biochem Behav; 2015 Aug; 135():177-81. PubMed ID: 26072692
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data.
Carai MA; Colombo G; Maccioni P; Gessa GL
CNS Drug Rev; 2006; 12(2):91-9. PubMed ID: 16958983
[TBL] [Abstract][Full Text] [Related]
27. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties.
Deiana V; Gómez-Cañas M; Pazos MR; Fernández-Ruiz J; Asproni B; Cichero E; Fossa P; Muñoz E; Deligia F; Murineddu G; García-Arencibia M; Pinna GA
Eur J Med Chem; 2016 Apr; 112():66-80. PubMed ID: 26890113
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.
Seo HJ; Kim MJ; Lee SH; Lee SH; Jung ME; Kim MS; Ahn K; Kim J; Lee J
Bioorg Med Chem; 2010 Feb; 18(3):1149-62. PubMed ID: 20045337
[TBL] [Abstract][Full Text] [Related]
29. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.
Klumpers LE; Fridberg M; de Kam ML; Little PB; Jensen NO; Kleinloog HD; Elling CE; van Gerven JM
Br J Clin Pharmacol; 2013 Dec; 76(6):846-57. PubMed ID: 23601084
[TBL] [Abstract][Full Text] [Related]
30. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation.
Zhang L; Lee NJ; Nguyen AD; Enriquez RF; Riepler SJ; Stehrer B; Yulyaningsih E; Lin S; Shi YC; Baldock PA; Herzog H; Sainsbury A
Diabetes Obes Metab; 2010 Jul; 12(7):591-603. PubMed ID: 20590734
[TBL] [Abstract][Full Text] [Related]
31. A method for parallel solid-phase synthesis of iodinated analogues of the CB1 receptor inverse agonist rimonabant.
Spivey AC; Tseng CC; Jones TC; Kohler AD; Ellames GJ
Org Lett; 2009 Oct; 11(20):4760-3. PubMed ID: 19778010
[TBL] [Abstract][Full Text] [Related]
32. Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB
Asproni B; Murineddu G; Corona P; Pinna GA
Molecules; 2021 Apr; 26(8):. PubMed ID: 33917187
[TBL] [Abstract][Full Text] [Related]
33. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
Serrano A; Del Arco I; Javier Pavón F; Macías M; Perez-Valero V; Rodríguez de Fonseca F
Neuropharmacology; 2008 Jan; 54(1):226-34. PubMed ID: 17467748
[TBL] [Abstract][Full Text] [Related]
34. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
35. Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation.
Tallett AJ; Blundell JE; Rodgers JR
Behav Pharmacol; 2007 Nov; 18(7):591-600. PubMed ID: 17912043
[TBL] [Abstract][Full Text] [Related]
36. Novel Fubinaca/Rimonabant hybrids as endocannabinoid system modulators.
Stefanucci A; Macedonio G; Dvorácskó S; Tömböly C; Mollica A
Amino Acids; 2018 Nov; 50(11):1595-1605. PubMed ID: 30145711
[TBL] [Abstract][Full Text] [Related]
37. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor.
Shim JY; Welsh WJ; Cartier E; Edwards JL; Howlett AC
J Med Chem; 2002 Mar; 45(7):1447-59. PubMed ID: 11906286
[TBL] [Abstract][Full Text] [Related]
38. Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.
Lu D; Dopart R; Kendall DA
Cell Stress Chaperones; 2016 Jan; 21(1):1-7. PubMed ID: 26498013
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and structure-activity relationship of novel diarylpyrazole imide analogues as CB1 cannabinoid receptor ligands.
Song KS; Kim MJ; Seo HJ; Lee SH; Jung ME; Kim SU; Kim J; Lee J
Bioorg Med Chem; 2009 Apr; 17(8):3080-92. PubMed ID: 19328001
[TBL] [Abstract][Full Text] [Related]
40. Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.
Jacobson LH; Commerford SR; Gerber SP; Chen YA; Dardik B; Chaperon F; Schwartzkopf C; Nguyen-Tran V; Hollenbeck T; McNamara P; He X; Liu H; Seidel HM; Jaton AL; Gromada J; Teixeira S
Naunyn Schmiedebergs Arch Pharmacol; 2011 Dec; 384(6):565-81. PubMed ID: 21947251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
